drugset
drugset / Trial / NCT05143996

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05143996 ↗

Phase 1 Recruiting 60 enrolled Cullinan Therapeutics Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Timeline

Start
2021-11-18
Primary completion
2027-01
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CLN-049 Unknown — Intravenous

Indications

acute myeloid leukemia myelodysplastic syndrome